Skip to content
DataLookout
Menu

NCT05723107

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Halted prematurely Show 5 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Final enrollment: 6 participants (planned 15)
    • Primary completion date changed from estimate of Nov 2027 to Nov 25, 2024
    • Study completion date changed from estimate of Mar 2028 to Feb 25, 2025
    • Site details revised
  2. Notable Primary completion date: Nov 2026 to Nov 2027
    • Study completion date: Mar 2027 to Mar 2028
    v7
  3. Notable Primary completion date: Nov 2025 to Nov 2026
    • Study completion date: Mar 2026 to Mar 2027
    v6
  4. Minor Start date: Mar 20, 2023 to Mar 31, 2023v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 2023 to Mar 20, 2023
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0
Timeframe: Up to Week 15

Secondary (5)

Percentage of Participants who Complete all 3 EUS-RFA Treatments
Disease-Free Survival from Diagnosis
Disease-Free Survival from First Study Procedure
Overall Survival From Diagnosis
Percentage of Participants who Report Post-Procedural Complications

Arms and interventions

Chemotherapy plus EUS-RFAExperimental

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer. Study participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing. Chemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15).

Drugs: Chemotherapy

Devices: Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

Sites

1 site in 1 country

  • Tisch HospitalNew York, New York, United States